Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-05T16:02:41.708Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term cognitive function following chemotherapy in patients with testicular cancer

Published online by Cambridge University Press:  01 March 2009

ANDERS DEGN PEDERSEN ,
PHILIP ROSSEN ,
MIMI YUNG MEHLSEN ,
CHRISTINA GUNDGAARD PEDERSEN ,
ROBERT ZACHARIAE  and
HANS VON DER MAASE
ANDERS DEGN PEDERSEN*
Affiliation:
Department of Neuropsychology Hammel Neurorehabilitation and Research Center, Aarhus University Hospital, Aarhus, Denmark
PHILIP ROSSEN
Affiliation:
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
MIMI YUNG MEHLSEN
Affiliation:
Department of Psychology, University of Aarhus, Aarhus, Denmark
CHRISTINA GUNDGAARD PEDERSEN
Affiliation:
Department of Psychology, University of Aarhus, Aarhus, Denmark
ROBERT ZACHARIAE
Affiliation:
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark Department of Psychology, University of Aarhus, Aarhus, Denmark
HANS VON DER MAASE
Affiliation:
Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
*
*Correspondence and reprint requests to: Anders Degn Pedersen, Department of Neuropsychology Hammel Neurorehabilitation and Research Center, Voldbyvej 15, DK-8450 Hammel, Denmark. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Cancer patients frequently report cognitive complaints following chemotherapy, but the results from the available studies, mainly of women with breast cancer, are inconsistent. Our aim was to compare cognitive function of men with testicular cancer (TC) who had orchiectomy and chemotherapy (bleomycin, etoposide, cisplatin) with men who had orchiectomy only or orchiectomy and radiotherapy. Thirty-six chemotherapy patients and 36 nonchemotherapy patients were tested 2–7 years after treatment for TC with standardized neuropsychological tests. Chemotherapy and nonchemotherapy patients displayed similar performances on cognitive tests (p values adjusted for multiple comparisons: .63–1.00). Moreover, there was no difference in the proportion of cognitively impaired patients in the chemotherapy group (5.6%) compared to the nonchemotherapy group (8.3%) (χ2 = 0.22, p = .64). Our results are discordant with previous findings indicating cognitive impairment following chemotherapy and suggest that TC patients do not need to fear long-term cognitive consequences following chemotherapy. (JINS, 2009, 15, 296–301.)

Keywords

Medical oncologyCognition disordersNeuropsychological testsbleomycinetoposidecisplatin
Type
Brief Communications
Information
Journal of the International Neuropsychological Society , Volume 15 , Issue 2 , March 2009 , pp. 296 - 301
Copyright
Copyright © INS 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Beck, A.T., Steer, R.A., & Brown, G.K. (1996). Manual: Beck Depression Inventory. San Antonio, TX: The Psychological Corporation, Hartcourt & Brace.Google Scholar
Cohen, S., Karmarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. Journal of Health and Social Behavior, 24, 385–396.CrossRefGoogle ScholarPubMed
Falleti, M.G., Sanfilippo, A., Maruff, P., Weih, L.A., & Phillips, K.A. (2005). The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. Brain and Cognition, 59, 60–70.CrossRefGoogle ScholarPubMed
Golden, C.J. & Freshwater, S.M. (2002). Stroop Color and Word Test. A manual for clinical and experimental uses. Wood Dale, IL: Stoelting Co.Google Scholar
Howiesen, D.B. & Lezak, M.D. (2004). Neuropsychological assessment (4th ed.) Oxford, UK: Oxford University Press.Google Scholar
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., Bishop, H., Hodson, N., Mitra, S., Sadler, G., Shah, E., Stein, R., Whitehead, S., & Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94, 828–834.Google Scholar
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., Classen, J., Clemm, C., Cohn-Cedermark, G., Culine, S., Daugaard, G., De Mulder, P.H., De Santis, M., de Wit, M., de Wit, R., Derigs, H.G., Dieckmann, K.P., Dieing, A., Droz, J.P., Fenner, M., Fizazi, K., Flechon, A., Fosså, S.D., Garcia Del Muro, X., Gauler, T., Geczi, L., Gerl, A., Germa-Lluch, J.R., Gillessen, S., Hartmann, J.T., Hartmann, M., Heidenreich, A., Hoeltl, W., Horwich, A., Huddart, R., Jewett, M., Joffe, J., Jones, W.G., Kisbenedek, L., Klepp, O., Kliesch, S., Koehrmann, K.U., Kollmannsberger, C., Kuczyk, M., Laguna, P., Leiva Galvis, O., Loy, V., Mason, M.D., Mead, G.M., Mueller, R., Nichols, C., Nicolai, N., Oliver, T., Ondrus, D., Oosterhof, G.O., Paz Ares, L., Pizzocaro, G., Pont, J., Pottek, T., Powles, T., Rick, O., Rosti, G., Salvioni, R., Scheiderbauer, J., Schmelz, H.U., Schmidberger, H., Schmoll, H.J., Schrader, M., Sedlmayer, F., Skakkebaek, N.E., Sohaib, A., Tjulandin, S., Warde, P., Weinknecht, S., Weissbach, L., Wittekind, C., Winter, E., Wood, L., & von der Maase, H. (2008). European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. European Urology, 53, 497–513.Google Scholar
Mehlsen, M.Y., Pedersen, A.D., Jensen, A.B. & Zachariae, R. (2008). No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pon.1398Google Scholar
Meyers, J.E. & Meyers, K.R. (1995). Rey Complex Figure Test and Recognition Trial. Odessa, FL: Psychological Assessment Resources.Google Scholar
Mortensen, E.L. & Gade, A. (1993). On the relation between demographic-variables and neuropsychological test-performance. Scandinavian Journal of Psychology, 34, 305–317.CrossRefGoogle Scholar
Nielsen, H., Knudsen, L., & Daugbjerg, O. (1989). Normative data for 8 neuropsychological tests based on a Danish sample. Scandinavian Journal of Psychology, 30, 37–45.CrossRefGoogle Scholar
Reitan, R.M. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8, 271–286.Google Scholar
Schagen, S.B., Boogerd, W., Muller, M.J., Huinink, W.T., Moonen, L., Meinhardt, W., & Van Dam, F.S.A.M. (2008). Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncologica, 47, 63–70.Google Scholar
Schagen, S.B., Muller, M.J., Boogerd, W., Mellenbergh, G.J., & Van Dam, F.S.A.M. (2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98, 1742–1745.CrossRefGoogle ScholarPubMed
Schretlen, D.J., Testa, S.M., Winicki, J.M., Pearlson, G.D., & Gordon, B. (2008). Frequency and bases of abnormal performance by healthy adults on neuropsychological testing. Journal of the International Neuropsychological Society, 14, 436–445.CrossRefGoogle ScholarPubMed
Suurmeijer, T.P.B.M., Doeglas, D.M., Briancon, S., Krijnen, W.P., Krol, B., Sanderman, R., Moum, T., Bjelle, A., & Van Den Heuvel, W.J.A. (1995). The measurement of social support in the European research on incapacitating diseases and social support—The development of the Social Support Questionnaire for Transactions (SSQT). Social Science & Medicine, 40, 1221–1229.Google Scholar
Van Dam, F.S.A.M., Schagen, S.B., Muller, M.J., Boogerd, W., von der Wall, E., Fortuyn, M.E.D., & Rodenhuis, S. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210–218.Google Scholar
van’t Spijker, A., Trijsburg, R.W., & Duivenvoorden, H.J. (1997). Psychological sequelae of cancer diagnosis: A meta-analytical review of 58 studies after 1980. Psychosomatic Medicine, 59, 280–293.CrossRefGoogle ScholarPubMed
Wechsler, D. (1997a). Wechsler Adult Intelligence Scale—third edition (WAIS-III). San Antonio, TX: The Psychological Corporation.Google Scholar
Wechsler, D. (1997b). Wechsler Memory Scale—third edition (WMS-III). San Antonio, TX: The Psychological Corporation.Google Scholar
Wieneke, M.H. & Dienst, E.R. (1995). Neuropsychological assessment of cognitive-functioning following chemotherapy for breast-cancer. Psycho-Oncology, 4, 61–66.CrossRefGoogle Scholar
Zevon, M.A. & Tellegen, A. (1982). The structure of mood change—An idiographic nomothetic analysis. Journal of Personality and Social Psychology, 43, 111–122.CrossRefGoogle Scholar